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ABSTRACT
Celecoxib, a nonsteroidal anti-inflammatory drug that selectively targets 
cyclooxygenase-2, is a promising cancer chemopreventive agent. However, safety 
concerns have been raised in clinical trials evaluating its ability to prevent colorectal 
adenomas. The rationale for the herein reported studies was to analyze genomic and 
epigenetic end-points aimed at investigating both the chemopreventive properties of 
celecoxib towards cigarette smoke-associated molecular alterations and its possible 
adverse effects. We carried out three consecutive studies in mice treated with either 
smoke and/or celecoxib. Study 1 investigated early DNA alterations (DNA adducts, 
oxidative DNA damage, and systemic genotoxic damage) and epigenetic alterations 
(expression of 1,135 microRNAs) in lung and blood of Swiss H mice; Study 2 evaluated 
the formation of DNA adducts in lung, liver, and heart; and Study 3 evaluated 
the expression of microRNAs in 10 organs and 3 body fluids of ICR (CD-1) mice. 
Surprisingly, the oral administration of celecoxib to smoke-free mice resulted in the 
formation of DNA adducts in both lung and heart and in dysregulation of microRNAs 
in mouse organs and body fluids. On the other hand, celecoxib attenuated smoke-
related DNA damage and dysregulation of microRNA expression. In conclusion, 
celecoxib showed pleiotropic properties and multiple mechanisms by counteracting 
the molecular damage produced by smoke in a variety of organs and body fluids. 
However, administration of celecoxib to non-smoking mice resulted in evident 
molecular alterations, also including DNA and RNA alterations in the heart, which may 
bear relevance in the pathogenesis of the cardiovascular adverse effects of this drug.
INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) 
are extensively used worldwide for the treatment of 
inflammation-related diseases. Among other applications, 
these agents provide a promising approach to the 
prevention of cancer, also including smoking-associated 
cancers [1]. The rationale for such a strategy is that 
chronic inflammation plays a key role at different stages 
of the carcinogenesis process [2, 3] and is crucial in 
tobacco smoke carcinogenesis [4]. NSAIDs interfere with 
the metabolism of arachidonic acid, a ω-6 essential fatty 
acid that is the substrate for different enzyme systems, 
including cyclooxygenases (COX), lipoxygenases, and 
cytochromes P450. Of the two COX enzymes, COX-1 is 
the housekeeping isoform, and the prostaglandins derived 
from COX-1 are involved in the homeostatic maintenance 
of the gastric mucosa. In contrast, COX-2 is the inducible 
isoform, expressed in response to certain stimuli such as 
mitogens, cytokines and growth factors, which has a pro-
inflammatory function [5].
Based on these mechanistic premises, selective 
COX-2 inhibitors, called coxibs, have been developed to 
improve gastrointestinal (GI) safety and tolerability. They 
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include drugs such as celecoxib, rofecoxib, valdecoxib, 
etoricoxib, and lumiracoxib. In particular, celecoxib 
(4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-
1-yl] benzene-1-sulfonamide, CAS 169590-42-5) was 
the first selective COX-2 inhibitor approved to treat 
patients with rheumatism and osteoarthritis. Upper GI 
complication rates in clinical trials have been reported to 
be significantly lower for celecoxib than for traditional 
nonselective NSAIDs [6–8]. While several coxibs have 
been withdrawn from the market due to safety concerns, 
and especially to cardiovascular adverse events [9, 10], 
celecoxib continues to be available for use in many 
countries [11]. This coxib is approved by the US Food 
and Drug Administration (FDA) (https://www.fda.gov/
ForConsumers/ConsumerUpdates/ucm240959.htm).
It has been shown that COX-2 downregulation 
inhibits colorectal carcinogenesis [10]. Moreover, 
based on reports that suggest an association between 
cigarette smoke (CS) and COX-2-associated risk to 
develop cancer, celecoxib is under scrutiny for its 
possible ability to prevent cancer and for antagonizing 
the carcinogenic properties of CS, the most important 
threat to human health. In humans, a case-control 
study showed that use of celecoxib and other coxibs 
reduces the lung cancer risk [12]. A trial of celecoxib in 
former smokers decreased the bronchial proliferation, 
evaluated by measuring the Ki-67 labeling index, and 
reduced lung nodules on computed tomography [13]. 
In mice, administration of celecoxib reduced oxidative 
stress-mediated alterations, due to its ability to boost 
the antioxidant defense system [14]. Coxibs and other 
NSAIDs are being tested in animal models of cancer 
chemoprevention [15]. Celecoxib reduced pulmonary 
inflammation but failed to affect lung tumorigenesis in 
mice treated with either 3-methylcholanthrene-butylated 
hydroxytoluene or urethane [16], while it prevented N-
butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder 
carcinomas in rats [17]. We showed that administration 
of celecoxib after weanling to Swiss H mice, which had 
been exposed to mainstream cigarette smoke (MCS) 
since birth and thereafter kept in filtered air for an 
additional 3.5 months, results in a variety of protective 
effects towards MCS-related carcinogenesis [18]. In 
particular, celecoxib significantly attenuated MCS-
induced alterations of inflammatory nature, including 
pulmonary emphysema, alveolar epithelial hyperplasias 
and lung microadenomas as well as urinary tract 
hyperplastic lesions. Moreover, the drug attenuated the 
yield of lung adenomas and showed some involvement in 
lowering the progression to cancer in the lung. However, 
in the same study celecoxib showed some hepatotoxicity 
in MCS-exposed mice [18], which is consistent with the 
demonstration that mediators derived from COX-2 have 
an important hepatoprotective function and accordingly 
the risk of drug-induced liver injury may be increased by 
COX-2 inhibition [19].
The herein reported studies aimed at investigating 
both the chemopreventive properties of celecoxib in MCS-
exposed mice and, at the same time, the possible adverse 
effects of this drug in smoke-free mice. To this purpose, we 
carried out three consecutive studies by using preclinical 
models that evaluated genomic and epigenetic end-
points. In particular, the first study, referred to as Study 1, 
investigated early genomic alterations related to treatment 
of mice early in life with MCS and/or celecoxib. DNA 
alterations were evaluated in terms of bulky DNA adducts 
and oxidative DNA damage in lung and of systemic 
genotoxic damage, and epigenetic alterations were 
evaluated in terms of expression of microRNAs (miRNAs) 
in both lung and blood. This is the same murine model that 
we have extensively used to demonstrate, in the medium 
term, the carcinogenicity of MCS [20] and its modulation 
by a variety of putative cancer chemopreventive agents 
[21], also including celecoxib itself [18]. One of the 
findings of that study was that, while inhibiting the 
formation of DNA adducts in MCS-exposed mice, 
celecoxib induces the evident formation of DNA adducts 
in the lung of smoke-free mice. In order to validate the 
results of this study, we carried out a second study (Study 
2) that specifically evaluated the selective formation of 
DNA adducts in the lung, liver, and heart of mice as related 
to exposure to MCS and administration of celecoxib. The 
third study (Study 3) was a quite extensive experiment that 
evaluated the expression of 1,135 miRNAs in 10 organs as 
related to the oral administration of celecoxib to adult mice, 
either smoke-free or MCS-exposed. Three body fluids were 
also examined, because extracellular miRNAs could serve 
as molecular biomarkers for diagnostic purposes applicable 
to both prevention and therapy of human diseases. The 
epigenetic alterations produced by MCS in this model, in 
the absence of chemopreventive agents, have previously 
been reported [22].
RESULTS
Study 1. Evaluation of genomic and epigenetic 
end-points in the lung and blood serum of 
newborn Swiss H mice as related to treatment 
with celecoxib and/or exposure to MCS
Survival and body weights
All mice survived after 10 weeks. The body weights 
in sham-exposed mice at weanling (about 4 weeks) were 
23.9 ± 0.75 g in males and 18.7 ± 0.87 g in females and 
grew progressively until the 10th week of life up to 40.0 
± 0.74 g and 29.2 ± 0.56 g, respectively. From the 3rd 
week onwards exposure to MCS resulted in a slight but 
statistically significant loss of body weight, which after 10 
weeks was 33.9 ± 0.62 g in males (P < 0.001 as compared 
to sham) and 27.3 ± 0.58 g in females (P < 0.05). As 
compared with sham-exposed mice, administration of 
celecoxib did not significantly affect the body weight, 
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which was 37.2 ± 0.97 g in males and 27.8 ± 0.80 g in 
females. Celecoxib did not change the slight body weight 
loss caused by MCS, which was 34.6 ± 1.55 g in males and 
26.7 ± 0.56 g in females. These figures were significantly 
lower than those recorded in sham-exposed mice (P < 
0.05 in both genders).
Bulky DNA adducts in the lung
Figure 1 shows examples of 32P autoradiographs 
obtained by testing a blank, a positive control (BPDE-dG), 
and the lung DNA from Swiss H mice, either untreated 
(sham-exposed) or exposed to MCS during the first 10 
weeks of life, and either untreated or treated with oral 
celecoxib for 6 weeks after weanling. Exposure of mice 
to MCS caused the formation of a massive diagonal 
radioactive zone (DRZ), which is typical of exposures to 
complex mixtures. Administration of celecoxib to MCS-free 
mice resulted in the formation of 3 autoradiographic spots 
that were absent in sham-exposed mice. It is not possible to 
ascertain whether the same DNA adducts were also present 
in the lung of MCS-exposed mice treated with this drug 
because the autoradiographic spots may have been masked 
and overwhelmed by the MCS-induced DRZ.
Table 1 (left column) reports the levels of pulmonary 
bulky DNA adducts in the 4 experimental groups, each one 
Figure 1: Examples of 32P autoradiographs obtained by testing a blank, a positive control (BPDE-dG), and the lung 
DNA from Swiss H mice, either untreated (sham-exposed) or treated with celecoxib for 6 weeks after weanling or 
exposed to MCS for 10 weeks since birth or exposed to MCS and treated with celecoxib.
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composed of 5 males (M) and 5 females (F). There were 
no significant intergender differences within any groups. 
Treatment of mice with celecoxib caused a significant, 
3.3-fold increase of DNA adducts, as compared with 
sham-exposed mice, which reflects the presence of the 
3 celecoxib-specific autoradiographic spots shown in 
Figure 1. The autoradiographic DRZ detected by 32P 
postlabeling in MCS-exposed mice corresponded to a 
14.5-fold increase of pulmonary DNA adduct levels in 
combined genders. Administration of celecoxib to MCS-
exposed mice significantly decreased the formation of 
DNA adducts in parallel to an evident attenuation of the 
DRZ (see Figure 1). In any case, DNA adduct levels in this 
group were still significantly higher (8.5-fold) compared 
to sham-exposed mice.
Oxidative DNA damage in the lung
Table 1 (right column) reports the levels of 
pulmonary 8-oxo-dGuo in the DNA of the same 4 
experimental groups of Swiss H mice used for measuring 
bulky DNA adducts. Again, there was no intergender 
differences within any group. Exposure of mice to MCS 
caused a significant oxidative DNA damage in the lung, 
as documented by a 2.9-fold, statistically significant 
increase of 8-oxo-dGuo levels. Administration of 
celecoxib to MCS-free mice did not affect 8-oxo-dGuo 
levels as compared with sham-exposed mice, whereas 
its administration to MCS-exposed mice significantly 
attenuated the oxidative DNA damage to such an extent 
that the 8-oxo-dGuo levels detected in MCS-exposed mice 
treated with celecoxib were undistinguishable from those 
detected in sham-exposed mice.
Systemic MCS genotoxicity
Modulation by celecoxib of the systemic 
genotoxicity was evaluated by measuring the frequency 
of MN NCE in the blood of mice exposed to MCS during 
the first 4 months of life, since birth, and/or treated 
with celecoxib after weanling until the 4th month of 
life. Exposure to MCS of both male and female mice 
resulted in significant increases in MN NCE frequency, 
as compared with sham-exposed mice (1.9 ± 0.14 vs. 1.3 
± 0.10 in males and 1.2 ± 0.06 vs. 0.8 ± 0.08 in females; 
P < 0.01 in both cases). Administration of celecoxib had 
no significant effect on the frequency of MN NCE either 
in MCS-free mice (1.4 ± 0.12 in males and 0.8 ± 0.08 in 
females) or in MCS-exposed mice (2.2 ± 0.15 in males 
and 1.2 ± 0.08 in females).
Modulation of pulmonary miRNAs
miRNA expression profiles were analyzed in the 
Swiss H mice belonging to the same 4 experimental groups 
examined for DNA end-points. Overall comparisons are 
shown in Figure 2, which reports the results of HCA (A) 
and bidimensional PCA (B). According to the former 
approach, it appears that Sham and MCS are allocated far 
away in the dendrogram. Celecoxib is close to Sham, and 
Table 1: Bulky DNA adducts and 8-oxo-dGuo evaluated by 32P postlabeling in the lungs of 40 Swiss H mice belonging 
to 4 experimental groups, as related to gender, exposure to MCS, and treatment with celecoxib
Treatment Gender Adducts/108 nucleotides
8-oxo-dGuo/
105 nucleotides
Sham M 1.3 ± 0.19 1.7 ± 0.25
F 1.2 ± 0.17 2.1 ± 0.20
M + F 1.3 ± 0.12 1.9 ± 0.17
Celecoxib M 4.3 ± 0.40b 1.6 ± 0.29
F 4.3 ± 0.34b 2.3 ± 0.28
M + F 4.3 ± 0.25b 1.9 ± 0.22
MCS M 17.9 ± 1.77b 5.0 ± 0.18b
F 20.0 ± 3.30b 6.0 ± 0.44b
M + F 18.9 ± 1.59b 5.5 ± 0.26
MCS + Celecoxib M 11.5 ± 2.08b,c 2.2 ± 0.27c
F 9.8 ± 1.91a,c 1.9 ± 0.22c
M + F 11.0 ± 0.30b,c 2.1 ± 0.17c
The results are means ± SE of the results obtained in the 5 mice composing each group. 
Statistical analysis: aP < 0.01 and bP < 0.001, as compared with sham-exposed mice; cP < 0.05 and dP < 0.001, as compared 
with MCS-exposed mice.
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MCS + celecoxib is linked to the MCS branch. Similarly, 
the Sham and MCS symbols fall in opposite quadrants at 
PCA. Celecoxib is in the quadrant nearby Sham, and MCS 
+ Celecoxib is close to MCS.
Figure 3 shows SPAs comparing the intensity of 
expression of pulmonary miRNAs either in sham-exposed 
mice vs. mice receiving celecoxib (upper panel), or in 
mice exposed to MCS, in the absence of celecoxib, vs. 
MCS-exposed mice receiving celecoxib (bottom panel). 
The miRNAs falling outside the diagonal 2-fold were 
mainly located in the lower part of the diagram, which 
includes miRNAs expressed at low intensity levels. As 
inferred from volcano-plot analyses (not shown), the 
number of miRNAs changing their expression more than 
2-fold and above the statistical significance threshold 
as compared with sham-exposed mice was 21 (1.9%) in 
celecoxib-treated mice, of which 19 were upregulated and 
2 were downregulated. The identity of these miRNAs and 
their main functions are reported in Table 2 (left column). 
The right column of the same table reports the miRNAs 
that were significantly dysregulated by celecoxib in MCS-
exposed mice. These included 11 miRNAs (1.0%), all of 
them upregulated by celecoxib both in MCS-free and 
MCS-exposed mice.
Figure 2: HCA (A) and bidimensional PCA (B) comparing the expression profiles of pulmonary miRNAs in sham-exposed mice and mice 
exposed to MCS during the first 10 weeks of life, either untreated or treated with celecoxib for 6 weeks after weanling.
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Modulation of blood serum miRNAs
The concentrations of miRNAs in blood serum 
were evaluated in the same Swiss H mice in which 
pulmonary miRNAs had been analyzed. The comparison 
of Figure 2A and Figure 4A shows at a glance that the 
concentrations of circulating miRNAs were much lower 
than those of pulmonary miRNAs, as inferred from the 
different color of the bands composing each column 
(blue, low intensity; red, high intensity). The distribution 
patterns of the experimental groups in the hierarchical tree 
(Figure 4A) shows that Sham and MCS are far away in the 
dendrogram. Celecoxib and MCS + Celecoxib are close 
in the same branch, which is linked to the MCS branch. 
Allocation of symbols according to bidimensional PCA 
(Figure 4B) shows that MCS and Sham are located far 
away from each other, with the MCS + Celecoxib symbol 
half-way between Sham and MCS and the Celecoxib 
symbol allocated from the same side of Sham.
SPA compared miRNA levels in the blood serum 
of sham-exposed mice vs. either celecoxib-treated mice 
(Figure 5, upper panel) or MCS-exposed mice (Figure 
Figure 3: SPAs comparing the expression of 1,135 pulmonary miRNAs either in sham-exposed mice vs. mice receiving 
celecoxib with the diet for 6 weeks, starting after weanling (upper panel), or in mice exposed to MCS during the first 
10 weeks of life, in the absence of celecoxib, vs. MCS-exposed mice receiving celecoxib (bottom panel). Each dot represents 
a miRNA, whose expression intensity can be inferred from the position in the x- and y-axes according to a color scale (blue, low; yellow, 
medium; orange to red, high). The diagonal belts indicate the 2-fold variation intervals. Symbols falling in the upper left area denote 
miRNA upregulation by celecoxib, and those falling in the bottom right area denote miRNA downregulation by celecoxib.
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5, middle panel) or MCS+celecoxib vs. MCS-exposed 
mice in the absence of chemopreventive agent (Figure 5, 
bottom panel). The concentration of several miRNAs was 
altered in the blood serum of celecoxib-treated mice as 
compared with sham-exposed mice. Identity, variations, 
and functions (as inferred from literature and Targetscan 
database) of the 18 miRNAs that were significantly 
modulated in blood serum by celecoxib, as compared 
with sham-exposed mice, are reported in Table 3 (left 
column). These miRNAs were identified by volcano-plot 
analysis (not shown) using 2-fold variation and P < 0.05 
significance ANOVA thresholds. Two of these miRNAs 
(miR-181, miR-208a) were also upregulated by celecoxib 
in the lung tissue (see Table 2). In addition, the miRNAs 
altered by celecoxib in blood serum included many 
miRNAs that were not modulated by this drug in the 
lung. Seven of the 18 blood miRNAs altered by celecoxib 
are liver specific, thus their presence in blood reflects 
celecoxib-induced modifications occurring in this organ. 
It is of interest that miR-208a, which has been related to 
the occurrence of heart damage, was well detectable in 
blood serum following celecoxib administration.
MCS was much more effective than celecoxib in 
altering miRNA expression in blood serum. The SPA 
reported in Figure 5 (bottom panel) shows that multiple 
miRNAs fall outside the 2-fold variation interval in 
MCS-exposed mice as compared with sham-exposed 
mice. Few miRNAs, mainly expressed at low levels, 
are downregulated (bottom right area, blue color dots 
falling outside the 2-fold variation interval). Conversely, 
the majority of MCS-altered miRNAs were upregulated 
and characterized by high level of expression (top 
left area, red dots falling outside the 2-fold variation 
interval). Identity, variations, and functions of the 30 
Table 2: List and functions of miRNAs, as inferred from volcano plot analyses, whose expression varied at least 
2-fold and to a statistically significant extent in the lung of Swiss H mice as a result of celecoxib administration either 
to sham-exposed mice or to MCS-exposed mice
miRNA Celecoxib/Sham MCS + Celecoxib/MCS Function
miR-106a 3.27 2.49 Cell adhesion, TNF activation, stress response
miR-181c 2.13 - NFkB stress response
miR-193 2.77 - Signal transduction
miR-196b 2.04 - TGF-beta
miR-208 2.22 - Heart damage
miR-290 2.21 2.82 Stem cell marker
miR-381 2.66 2.15 Cell proliferation
miR-471 2.97 2.42 LC3-associated phagocytosis
miR-511 2.28 - Inflammation, monocyte activation
miR-582 3.36 - Cell proliferation, apoptosis
miR-615 2.37 2.92 Macrophage activation
miR-701 2.54 - NA
miR-758 3.28 2.71 Cell proliferation, apoptosis
miR-1193 0.41 - Cell proliferation, apoptosis
miR-1195 0.40 - MAP kinase signaling pathway, cytochrome CYP2s1 activity
miR-1247 2.30 2.00 Fibroblasts activation, increase of pro-inflammatory gene expression
miR-1251 2.83 3.17 Signal transduction by targeting IGF1
miR-3070 3.38 2.58 NA
miR-3085 2.27 4.17 Cartilage homeostasis and destruction
miR-3109 2.04 2.03 NA
miR-5617 2.13 - NA
NA, not available.
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blood miRNAs that were significantly altered by MCS 
compared with sham-exposed mice, as identified by 
volcano-plot analysis (not shown), are reported in 
Table 3. MCS induced a prevalent upregulation of 
miRNAs. In fact, as many as 29 out of the 30 altered 
miRNAs were upregulated.
Celecoxib was effective in counteracting the effect 
of MCS on 7 blood miRNAs (Table 3). This finding 
reflects chemopreventive mechanisms activated by this 
drug in MCS target organs, mainly including the lung but 
also kidney and skin, as indicated by the tissue specificity 
of the modulated miRNAs (see Table 3, last column on 
the right).
Study 2. Bulky DNA adducts in lung, liver, and 
heart of ICR (CD-1) mice exposed to MCS and/
or treated with celecoxib
Figure 6 shows examples of 32P autoradiographs 
obtained by testing the lung, liver, and heart DNA from ICR 
(CD-1) mice, as related to treatment with celecoxib and/
or exposure to MCS. Exposure of mice to MCS resulted 
in the formation of massive DRZs in both heart and lung, 
whereas in the liver such an effect was marginal. Treatment 
of smoke-free mice with celecoxib caused the formation of 
3 autoradiographic spots in the lung, having a localization 
similar to the one observed in the previous study (see 
Figure 4: HCA (A) and bidimensional PCA (B) comparing the expression profiles of miRNAs in the blood serum of sham-exposed mice 
and MCS-exposed mice, either untreated or treated with celecoxib as described in the legend to Figure 2.
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Figure 1), and of an evident spot in the heart, which was 
not discernible in the liver. Administration of celecoxib to 
MCS-exposed mice resulted in a sharp reduction of DRZs in 
both lung and heart. While the celecoxib-related spots were 
no longer detectable in the lung, also because they were 
partially masked by the DRZ, the same celecoxib-related 
spot detected in the heart of smoke-free mice was attenuated 
but still visible in the heart of MCS-exposed mice.
Table 4 reports the levels of bulky DNA adducts 
(means ± SE of 10 mice per gender) in the three examined 
organs. In the lung, exposure of mice to MCS caused a 
considerable and statistically significant increase of DNA 
adduct levels in both males (10.7-fold) and females (12.1-
fold), with an average 11.5-fold increase in combined 
genders. Likewise, exposure of mice to MCS caused a 
considerable and statistically significant increase of DNA 
adduct levels in in the heart of both males (4.6-fold) and 
females (5.9-fold), with an average 5.1-fold increase in 
combined genders. The slight differences between males 
and females were not statistically significant.
Although to a lower extent, being attributable 
to isolated spots rather than to a DRZ, the increases of 
Figure 5: SPAs comparing the expression of 1,135 miRNAs in the blood serum of sham-exposed mice vs. either 
celecoxib-treated mice (upper panel) or MCS-exposed mice (middle panel) or MCS + celecoxib vs. mice exposed to 
MCS in the absence of celecoxib (bottom panel). Each dot represents a miRNA, whose expression intensity can be inferred from 
the position in the x- and y-axes according to a color scale (blue, low; yellow, medium; orange to red, high). The diagonal belts indicate 
the 2-fold variation intervals.
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Table 3: Fold variations, main functions, and tissue specificity of miRNAs that were significantly modulated in 
the blood serum of Swiss H mice, either treated with celecoxib (left column) or exposed to MCS (right column), as 
compared with sham-exposed mice
miRNA
Fold variation
Function Tissue specificityCelecoxib/
Sham
MCS/
Sham
MCS/
MCS+Celecoxib
miR-9 - 3.12 Apoptosis Brain
miR-21/miR-21a 2.65 2.25 Tumor suppressor gene PTEN, cell proliferation
Lung, kidney, bladder, 
liver
miR-30a - 3.02 2.75
Intercellular adhesion, protein 
repair, NFκB activation, cell 
cycle, EGF activation, stem cell 
recruitment, multidrug resistance
Kidney, lung, heart
miR-125b 2.64 1.54
Oncogene ERBB, vitamin D 
receptor, inflammation, gene 
transcription
Lung, cervix, brain, ovary, 
prostate, bladder
miR-181/
miR-181b
2.89 2.79 NFκB stress response
Brain, thymus, kidney, 
lunga
miR-184 - 3.44 Cell differentiation Epithelia, eye, tongue, brain, lunga
miR-185 2.70 1.86
Cell proliferation, cholesterol 
metabolism
Liver, breast, prostate, 
ovary
miR-208 2.63 - Heart damage Heart, lunga
miR-211 - 4.35 2.88 Stress response, oncogene (TGF) suppression Skin, pancreas
miR-222 2.42 1.53 Angiogenesis, cell proliferation Prostate, lung, bladder
miR-296 2.83 3.05
Thioredoxin and cysteine 
synthesis (antioxidants), 
inflammation
Muscle, prostate, lung, 
bladder
miR-301a 2.60 2.59 Stress response, oncogene activation
Liver, stomach, pancreas, 
lunga
miR-320 - 3.28 Protein repair, intracellular trafficking, cell proliferation Bladder, cervix, liver, lung
miR-328 2.53 - Stem cell differentiation Intestine, heart
miR-329 - 3.22 Cell proliferation, coagulation Platelet, brain, lunga
miR-335 2.40 2.42 2.51 Cell proliferation, apoptosis Lung
miR-341 - 3.31 Cell differentiation Lunga
miR-361 2.88 1.88 Angiogenesis Blood vessels
miR-374b - 3.00 2.63 Stress response Lung
miR-379 2.92 1.87
Signal transduction, ATP 
metabolism Liver
miR-490 2.48 - Stress response, cell proliferation Lung
miR-551/
miR-551b 2.43 1.48
DNA repair, inflammation, cell 
proliferation Liver
(Continued )
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DNA adduct levels in smoke-free mice treated with 
celecoxib were evident and statistically significant both 
in the lung (2.9-fold in males, 2.5-fold in females, and 
2.7-fold in combined genders) and in the heart (2.1-fold 
in males, 2.4-fold in females, and 2.2-fold in combined 
genders). On the other hand, administration of celecoxib 
significantly attenuated DNA adduct levels in the lung 
of MCS-exposed mice (1.5-fold decrease in males, 1.7-
fold decrease in males, and 1.6-fold decrease in combined 
genders as compared with MCS-exposed mice in the 
absence of celecoxib). A similar protective effect was 
detected in the heart of MCS-exposed mice, an effect 
that was not statistically significant in males (1.1-fold 
decrease) but reached the statistically significant threshold 
in both females (1.5-fold decrease) and combined genders 
(1.3-fold decrease). In any case, DNA adduct levels in 
both lung and heart of MCS-exposed mice treated with 
celecoxib were still much higher than those detected in 
sham-exposed mice. In the liver, the levels of DNA adducts 
in mice treated with either MCS and/or celecoxib varied 
to a statistically significant extent but the differences 
were very modest and of the same order of magnitude for 
all treatments. In fact, the increases over sham-exposed 
mice were 1.5-fold in males, 1.6-fold in both females and 
combined genders of MCS-exposed mice in the absence of 
celecoxib; 1.3-fold in males, 1.5-fold in females, and 1.4-
fold in combined genders of MCS-free mice treated with 
celecoxib; and 1.3-fold in males, 1.5-fold in females, and 
1.4-fold in mixed genders of MCS-exposed mice treated 
with celecoxib.
Study 3. Modulation by celecoxib of miRNA 
expression profiles in 10 organs and 3 body 
fluids of young Swiss ICR (CD-1) mice, either 
smoke-free or MCS-exposed
Survival and body weights
All mice survived after 8 weeks of treatment. The 
body weights in sham-exposed mice at the beginning of 
the study were 38.3 ± 0.83 in males and 28.8 ± 0.82 in 
females and grew progressively until reaching a plateau 
after 3 weeks. After 8 weeks, the body weights were 42.3 
± 1.09 in males and 37.5 ± 1.16 in females. From the 3rd 
week onwards, exposure to MCS resulted in a slight but 
statistically significant loss of body weight, which after 8 
weeks was 39.4 ± 0.70 in males (P < 0.05 as compared to 
sham) and 31.7 ± 1.22 in females (P < 0.01).
As compared with sham-exposed mice, 
administration of celecoxib at high dose (1,600 mg/kg 
diet) did not significantly affect the body weight, which 
was 42.1 ± 0.61 in males and 31.5 ± 0.98 in females. 
Likewise, administration of celecoxib at low dose (20 mg/
kg diet) to smoke-free female mice did not significantly 
affect the body weight, which was 32.6 ± 1.82. The slight 
body weight loss caused by MCS was not significantly 
affected by administration of celecoxib either at high dose 
miRNA
Fold variation
Function Tissue specificityCelecoxib/
Sham
MCS/
Sham
MCS/
MCS+Celecoxib
miR-695 2.90 2.27 NA Lunga
miR-802 0.39 - Glucose metabolism Liver
miR-804 2.86 2.36
Cell proliferation, collagen 
production, Ras activation Liver, lung
miR-1199 - 3.13 2.62 NA Lunga
miR-1224 - 3.66 Cell proliferation inhibition, angiogenesis
Liver, blood vessels,
lunga
miR-1298 - 5.81 Cell proliferation, apoptosis Brain
miR-1894 - 0.43 Cell proliferation, migration Breast
miR-1900 - 2.39 Cell homeostasis NA
miR-1934 - 4.13 Inflammatory response Adipose tissue
miR-1964 2.61 NA NA
miR-1983 - 2.38 Aldosterone signaling pathway Kidney
miR-3068 - 2.56 2.12 NA NA
miR-3080 - 4.93 2.33 NA NA
NA, not available. aThis study.
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(34.6 ± 1.55 in males and 26.7 ± 0.56 in females) or at low 
dose (30.9 ± 1.24 in females).
Effect of high dose celecoxib on miRNA 
expression in 10 organs and 3 body fluids of 
mice, either sham-exposed or MCS-exposed
Administration of high dose celecoxib (1,600 mg/kg 
diet) altered the position of miRNA profiles as compared 
to sham-exposed mice, as evaluated by bidimensional 
PCA (Figure 7C vs. Figure 7A). The organs changing 
the PCA quadrant compared to Sham-treated mice as 
a consequence of celecoxib administration were the 
stomach, colon, spleen, kidney, lung, and skeletal muscle. 
The influence of celecoxib on miRNA expression in body 
fluids was less remarkable. The organs changing PCA 
quadrant as a consequence of celecoxib administration 
to MCS-exposed mice (Figure 7D, as compared to MCS-
exposed mice in the absence of the drug (Figure 7B), were 
lung, kidney, bladder, and muscle. The effects of celecoxib 
were also detectable in body fluids of MCS-exposed mice, 
especially in urine and BALF.
The celecoxib organotropism was evaluated with 
more details by comparative SPA (Figure 8). According 
to the number of miRNAs varying their expression more 
than 2-fold as a consequence of celecoxib treatment 
Figure 6: Examples of 32P autoradiographs obtained by testing the lung, heart, and liver DNA from ICR (CD-1) mice, 
either untreated (sham-exposed) or treated with celecoxib for 6 weeks after weanling or exposed to MCS for 10 weeks 
since birth, in the absence of celecoxib, or exposed to MCS and treated with celecoxib.
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Table 4: Bulky DNA adducts evaluated by 32P postlabeling in the lungs, heart and liver of 80 ICR (CD-1) mice, as 
related to gender, exposure to MCS, and treatment with celecoxib
Treatment Gender
Adducts/108 nucleotides
Lung Heart Liver
Sham M 1.5 ± 0.18 1.6 ± 0.09 1.2 ± 0.09
F 1.5 ± 0.20 1.5 ± 0.05 1.2 ± 0.09
M + F 1.5 ± 0.12 1.6 ± 0.05 1.2 ± 0.06
Celecoxib M 4.4 ± 0.56c 3.3 ± 0.18c 1.6 ± 0.12a
F 3.7 ± 0.31c 3.6 ± 0.37c 1.8 ± 0.08c
M + F 4.0 ± 0.31c 3.4 ± 0.17c 1.7 ± 0.08a
MCS M 16.1 ± 0.97c 7.4 ± 0.54c 1.8 ± 0.17b
F 18.2 ± 1.46c 8.9 ± 0.73c 1.9 ± 0.17b
M + F 17.2 ± 0.87c 8.2 ± 0.45c 1.9 ± 0.13c
MCS + Celecoxib M 10.5 ± 0.89c,e 6.9 ± 0.35c 1.6 ± 0.11a
F 10.8 ± 1.09c,e 6.1 ± 0.25c,d 1.8 ± 0.10c
M + F 10.7 ± 0.69c,e 6.4 ± 0.23c,d 1.7 ± 0.08c
The results are means ± SE of the results obtained in 10 mice per group.
Statistical analysis: aP < 0.05, bP < 0.01, and cP < 0.001, as compared with sham-exposed mice; d < 0.01 and eP < 0.001, as 
compared with MCS-exposed mice.
Figure 7: Bidimensional PCA comparing the expression profiles of miRNAs in 10 organs and 3 body fluids of adult ICR (CD-1) mice, 
either sham-exposed (A) or exposed to MCS for 8 weeks (B), and either administered celecoxib to smoke-free mice (C) or MCS-exposed 
mice (D).
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(i.e., being located outside the diagonal area limited by 
green lines in Figure 8), it appears that the preferentially 
targeted organs were lung and bladder. An intermediate 
effect was detected in liver, kidney, spleen, colon, and 
stomach; only minimal effects were observed in heart, 
skeletal muscle, and brain. miRNA expression in body 
fluids was markedly affected by celecoxib treatment, 
especially in blood and BAL, and remarkable effects 
were also detected in urine. Figure 9 shows the overall 
protective effects of celecoxib from MCS as evaluated 
by SPA. According to the number of miRNAs varying 
their expression more than 2-fold as a consequence of 
celecoxib administration to MCS-exposed mice (i.e., 
being located outside the diagonal area limited by green 
lines in Figure 9), the preferentially protected organs by 
celecoxib were bladder, kidney, and spleen; intermediate 
effects were detectable in stomach, colon, skeletal 
muscle, heart, liver, and lung; no effect was detectable 
in the brain. As to body fluids, blood and BAL were 
more sensitive than urine in detecting the protective 
effects of celecoxib against miRNA alteration induced 
by MCS.
Table 5 provides a list reporting the identity and 
functions of miRNAs modulated by celecoxib in 9 organs 
and 3 body fluids of ICR (CD-1) mice, either sham-
exposed (superscripts a) or MCS-exposed (superscripts 
b). The brain is not reported in that table because no 
brain miRNA was significantly modulated by celecoxib. 
As inferred from Table 5, 30 miRNAs were modulated 
by celecoxib in the urinary bladder (upregulated/
downregulated in MCS-free mice: 0/10; upregulated/
downregulated in MCS-exposed mice: 8/12); 27 in kidney 
(7/20; 0/0); 20 in stomach (2/12; 3/3); 18 in liver (0/15; 
2/1); 18 in blood serum (2/11; 2/3); 17 in spleen (2/7; 1/7); 
16 in skeletal muscle (0/0; 6/10); 15 in lung (14/0; 0/1); 7 
in colon (1/4; 0/2) and in BALF (2/3; 0/2); 3 in heart (0/2; 
0/1) and urines (0/3; 0/0); and 0 in brain.
Thus, on the whole upregulation of miRNA 
expression by celecoxib in smoke-free mice was by far 
prevalent in the lung, whereas the balance was in favor of 
downregulation in other organs, such as urinary bladder, 
kidney, stomach, and spleen, and body fluids (blood serum 
and urines). In MCS-exposed mice the number of miRNAs 
modulated by celecoxib was lower as compared with MCS-
free mice, with the exception of the urinary bladder and 
skeletal muscle, in which downregulation was prevailing.
Several miRNAs were upregulated in organs of 
MCS-free mice while being downregulated in the same 
organs of MCS-exposed mice, which reflects the ability of 
celecoxib to alter the physiological miRNA expression but, 
at the same time, to counteract MCS-related alterations. 
In addition, a number of miRNAs, often clustered 
Figure 8: SPAs comparing the expression of 1,135 pulmonary miRNAs in 10 organs and 3 body fluids of ICR (CD-1) 
mice in celecoxib-treated vs. sham-exposed mice. Each dot represents a miRNA, whose expression intensity can be inferred from 
the position in the x- and y-axes according to a color scale (blue, low; yellow, medium; orange to red, high). The diagonal belts indicate the 
2-fold variation intervals. Symbols falling in the upper left area denote miRNA upregulation by celecoxib, and those falling in the bottom 
right area denote miRNA downregulation by celecoxib.
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in miRNA families, were modulated by celecoxib in 
multiple targets, sometimes with high fold variations. 
For instance, members of the miR-30 family were 
extensively downregulated by celecoxib. In fact, this drug 
downregulated miR-30b in the liver, heart, kidney and 
colon of MCS-free mice as well as in the heart, spleen, and 
urinary bladder of MCS-exposed mice; miR-30c-2-3p was 
downregulated by celecoxib in the liver (9-fold) and kidney 
(14-fold) of MCS-free mice and in the spleen and urinary 
bladder (7-fold) of MCS-exposed mice; miR-30c-2-5p was 
downregulated in the heart, kidney (13-fold), spleen (7-
fold), urinary bladder (10-fold), stomach, blood serum and 
BALF of MCS-free mice and in the skeletal muscle and 
colon of MCS-exposed mice; miR-30e was downregulated 
in the liver (10-fold), kidney (8-fold), urinary bladder 
(8-fold), and blood serum of MCS-free mice, whereas it 
was upregulated in the lung, urinary bladder (6-fold) and 
skeletal muscle (9-fold) of MCS-exposed mice. Within 
the miR-125 family, celecoxib downregulated miR-125a 
in the liver, kidney, spleen, and stomach of MCS-free 
mice and in the skeletal muscle and stomach of MCS-
exposed mice, in which this miRNA was upregulated in 
the liver; miR-125b was downregulated by celecoxib in 
the lung, kidney, spleen and stomach of MCS-free mice 
and in the urinary blood, skeletal muscle (11-fold) and 
stomach (9-fold) of MCS-exposed mice. Within the miR-
185 family, celecoxib downregulated miR-185-3p in the 
kidney and stomach of MCS-free mice and in the spleen 
and skeletal muscle of MCS-exposed mice; miR-185-5p 
was downregulated in the liver, kidney (as much as 25-
fold), urinary bladder (20-fold), colon (8-fold) and blood 
serum of MCS-free mice and in the lung, spleen, urinary 
bladder (14-fold) and blood serum of MCS-exposed mice. 
Within the miR-301 family, celecoxib downregulated miR-
301 in the liver, kidney (7-fold), urinary bladder (8-fold) 
and colon (6-fold) of MCS-free mice and miR-301b in the 
liver, kidney, urinary bladder and skeletal muscle of MCS-
free mice and in the urinary bladder of MCS-exposed 
mice. Furthermore, celecoxib downregulated miR-196a-
5p in the liver, kidney, spleen, urinary bladder and colon 
of MCS-free mice, whereas the levels of the same miRNA 
were increased in blood serum. Celecoxib downregulated 
miR-208a-5p in the kidney, stomach, BALF and urines 
of MCS-free mice and in the urinary bladder of MCS-
exposed mice. It caused a strong upregulation of miR-361 
in the lung (8-fold), whereas it downregulated this miRNA 
in the liver, kidney, stomach and blood serum of MCS-free 
mice as well as in the spleen and skeletal muscle of MCS-
exposed mice. miR-511 was upregulated by celecoxib in 
the kidney of MCS-free mice and in the liver an skeletal 
muscle (5-fold) of MCS-exposed mice, in which this 
miRNA was downregulated in the stomach. miR-695 was 
Figure 9: SPAs comparing the expression of 1,135 pulmonary miRNAs in 10 organs and 3 body fluids of ICR (CD-1) 
mice, either MCS-exposed and treated with celecoxib or MCS-exposed in the absence of celecoxib. Each dot represents 
a miRNA, whose expression intensity can be inferred from the position in the x- and y-axes according to a color scale (blue, low; yellow, 
medium; orange to red, high). The diagonal belts indicate the 2-fold variation intervals. Symbols falling in the upper left area denote 
miRNA upregulation by celecoxib, and those falling in the bottom right area denote miRNA downregulation by celecoxib.
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Table 5: MiRNAs modulated by high dose celecoxib (1,600 mg/Kg diet) in 9 organs and 3 body fluids of female ICR 
(CD-1) mice, either sham-exposed or MCS-exposed
miRNA Lung Liver Heart Kidney Spleen Urinary bladder
Skeletal 
muscle Colon Stomach
Blood 
serum BALF Urine Main functions
miR-21a 0.39a 0.27a Tumor suppressor gene PTEN, cell proliferation
miR-30a 2.04a
Intercellular adhesion, protein repair, NFkB 
activation, cell cycle, EGF activation, stem 
cell recruitment, multidrug resistance
miR-30b 0.26a 0.41
a
0.36b
0.25a 0.31b 0.22b 0.23a
Intercellular adhesion, protein repair, NFkB 
activation, cell cycle, EGF activation, stem 
cell recruitment, multidrug resistance
miR-30c-1-3p 0.33b 0.25a
Intercellular adhesion, protein repair, NFkB 
activation, cell cycle, EGF activation, stem 
cell recruitment, multidrug resistance
miR-30c-2-3p 0.11a 0.07a 0.30b 0.14b
Intercellular adhesion, protein repair, NFkB 
activation, cell cycle, EGF activation, stem 
cell recruitment, multidrug resistance
miR-30c-5p 0.46a 0.08a 0.15a 0.10a 0.23b 0.33b 0.40a 0.26a* 0.26a
Intercellular adhesion, protein repair, NFkB 
activation, cell cycle, EGF activation, stem 
cell recruitment, multidrug resistance
miR-30d 2.64a 2.58b
Intercellular adhesion, protein repair, NFkB 
activation, cell cycle, EGF activation, stem 
cell recruitment, multidrug resistance
miR-30e 3.10a 0.10a 0.12a 0.13
b 
0.12a 0.11
b 0.28a
Intercellular adhesion, protein repair, NFkB 
activation, cell cycle, EGF activation, stem 
cell recruitment, multidrug resistance
miR-106a 2.65b 2.03a Cell adhesion, TNF activation, stress response
miR-125a 0.35
a
2.08b
0.31a 0.49a 0.22b 0.32
a
0.35b
Oncogene ERBB, vitamin D receptor, 
inflammation, gene transcription
miR-125b 2.16a 0.23a 0.29a 0.42b 0.09b 0.28
a
0.11b
Oncogene ERBB, vitamin D receptor, 
inflammation, gene transcription
miR-181b 4.08a 2.43b 2.60b 0.48a NFkB stress response
miR-181c-3p 0.40a NFkB stress response
miR-181c-5p 2.83b 4.78b NFkB stress response
miR-181d 2.78a 2.73b 0.46a NFkB stress response
miR-185-3p 0.39a 0.29b 0.37b 0.29a Cell proliferation, cholesterol metabolism
miR-185-5p 0.47b* 0.06a 0.04a 0.48b 0.07
b
0.05a 0.12
a 0.38
a* 
0.35b Cell proliferation, cholesterol metabolism
miR-193b 0.30b 2.11a Signal transduction
miR-196a-3p 0.20a TGF-beta
miR-196a-5p 0.25a 0.27a 0.28a 0.18b 0.34a 2.13b TGF-beta
miR-208a-3p 0.15a Heart damage
miR-208a-5p 0.21a 0.18b 0.43a 0.47a 0.45a Heart damage
miR-208b 2.66a 0.18b 2.02b Heart damage
miR-211 2.30b Stress response, oncogene (TGF) suppression
miR-222 2.76a Angiogenesis, cell proliferation
miR-290 0.15a 0.12a* Stem cell marker
miR-296 2.15a* Thioredoxin and cysteine synthesis (antioxidants), Inflammation
miR-301a 0.22a 0.14a 0.13a 0.18a Stress response, oncogene activation
miR-301b 0.30a 0.41a 0.43
b
0.41a 0.30
b Stress response, oncogene activation
(Continued )
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miRNA Lung Liver Heart Kidney Spleen Urinary bladder
Skeletal 
muscle Colon Stomach
Blood 
serum BALF Urine Main functions
miR-335-3p 0.26a 0.24a 0.25
b
0.22a Cell proliferation, apoptosis
miR-335-5p 0.05a 0.07a Cell proliferation, apoptosis
miR-361 8.09a 0.33a 0.20a 0.35b 0.34b 0.23a 0.29a Angiogenesis
miR-374b 2.06a 0.48a Cell proliferation, invasion
miR-379 0.42a Signal transduction
miR-381 0.42b Cell proliferation
miR-471 3.72a 0.14a 2.99a 3.20b 2.02b 0.26a NA
miR-511-3p 0.18a Inflammation, monocyte activation
miR-511-5p 2.06b 2.33a 4.52b 0.43b Inflammation, monocyte activation
miR-551b 3.08a* DNA repair, inflammation, cell proliferation
miR-615 0.24a 3.53b 0.33a Macrophage activation
miR-695 0.33a 0.44b 0.17b 0.21a 0.28a 0.17a NA
miR-701-3p
2.78a
2.32b 4.84
b 0.25b 0.47b 0.30a NA
miR-701-5p 0.30b NA
miR-758 2.17b Cell proliferation, apoptosis
miR-802-3p 0.14a 0.16a 4.86b 2.99b Glucose metabolism
miR-802-5p 0.22a Glucose metabolism
miR-804 3.71a 0.23a Cell proliferation,collagen production, Ras activation
miR-1195 2.71b
MAP kinase signaling pathway, cytochrome 
CYP2s1 activity
miR-1199 2.66b 3.03b 0.21a NA
miR-1247 6.08a
Fibroblasts activation, increase of pro-
inflammatory gene expression
miR-1251 2.63a 2.41b Signal transduction by targeting IGF1
miR-1945 2.89a 0.45a 0.38a* NA
miR-1952 2.14b NA
miR-1964-3p 2.87a 2.97a NA
miR-1964-5p 0.15a 0.22
b
0.14a 0.22
b 0.23a 0.13a 0.31
b
0.17a
NA
*Also modulated by low dose celecoxib (20 mg/Kg diet). NA, not available.
The reported values indicate the fold variation of miRNA expression either in celecoxib-treated vs. sham-exposed micea or in MCS-exposed mice treated with celecoxib vs. 
MCS-exposed mice in the absence of celecoxibb.
downregulated in the kidney, stomach, blood serum and 
BALF of MCS-free mice and in the urinary bladder and 
skeletal muscle (6-fold) of MCS-exposed mice. miR-701-
3p was upregulated in the spleen and downregulated in the 
BALF of MCS-free mice, whereas it was upregulated in 
the spleen and urinary bladder (5-fold) and downregulated 
in the skeletal muscle and blood serum of MCS-exposed 
mice. miR-802-3p was downregulated in the liver (7-fold) 
and kidney (6-fold) of MCS-free mice and upregulated in 
the urinary bladder (5-fold) and stomach (3-fold) of MCS-
exposed mice. miR-1945 was upregulated in the kidney, 
whereas its levels decreased in both BALF and urines 
of MCS-free mice. miR-1964-5p was downregulated by 
celecoxib in the kidney (7-fold), stomach (4-fold), blood 
serum (8-fold) and BALF (6-fold) of MCS-free mice as 
well as in the urinary bladder (5-fold), skeletal muscle (5-
fold) and BALF (3-fold) of MCS-exposed mice.
Effect of low dose celecoxib on miRNA 
expression in 10 organs and 3 body fluids of 
mice, either sham-exposed or MCS-exposed
The effects of low dose celecoxib (20 mg/kg diet) 
were evaluated in the lung, blood serum, and urines of 
female mice, either smoke-free or MCS-exposed. In all 
body compartments, the number of miRNAs modulated by 
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celecoxib when administered at low dose was by far lower 
than the number observed at high dose, both in the absence 
and in the presence of MCS exposure. It is of interest that 
the same pulmonary miRNAs that were modulated by 
celecoxib at low dose (identified with an asterisk in Table 
5) were also modulated by celecoxib at high dose, thus 
being identifiable as sensitive and specific biomarkers of 
celecoxib effect in lung.
In particular, in lung low dose celecoxib modulated 
the expression of miR-296 (2.4-fold upregulation) and 
miR-551b (2.2-fold upregulation) as compared to sham, 
and it downregulated the expression of miR185 (2.8-
fold downregulation) as compared to MCS-exposed 
mice. Accordingly, the number of miRNAs modulated 
by celecoxib at low dose was only 3 as compared to the 
14 miRNAs modulated in lung by celecoxib at high 
dose (see Table 5). In blood serum, low dose celecoxib 
modulated the expressions of miR30c-5p (2.9-fold 
downregulation), as compared to sham, and of miR-185 
(2.1-fold downregulation) as compared to MCS-exposed 
mice. Accordingly, the number of miRNAs modulated by 
celecoxib at low dose was only 2 as compared to the 11 
miRNAs modulated by celecoxib at high dose in the blood 
(see Table 5). In urine, low dose celecoxib modulated the 
expression of both miR-290 (2.4-fold downregulation) 
and miR-1945b (2.4-fold downregulation) as compared 
to sham. Accordingly, the number of miRNAs modulated 
by celecoxib at low dose in urine was 2 as compared to 3 
miRNAs modulated by celecoxib at high dose (see Table 5).
DISCUSSION
The present article reports the results of three 
consecutive studies evaluating the effects of treatment 
with celecoxib and/or exposure to MCS on genomic and 
miRNA alterations in the lung and blood serum of newborn 
Swiss H mice (Study 1), occurrence of bulky DNA adducts 
in the lung, liver, and heart of newborn ICR (CD-1) mice 
(Study 2), and alterations of miRNA expression profiles in 
10 organs and 3 body fluids of young Swiss ICR (CD-1) 
mice (Study 3). The overall results obtained demonstrate 
that this NSAID causes genomic and epigenetic alterations 
in the lung, heart, and other body compartments of MCS-
free mice but, on the other hand, its administration exerts 
protective effects towards imbalances of the same end-
points in smoking mice.
In the interpretation of the results obtained it 
should be kept in mind that in Study 3 administration of 
celecoxib started short before beginning of exposure to 
MCS, whereas in both Study 1 and Study 2 administration 
of celecoxib started about one month after beginning of 
exposure to MCS, as soon as the mice became able to 
eat autonomously. In Study 1 and Study 2 the mice were 
treated with celecoxib during the 6 weeks following 
weanling, i.e., from the 5th to the 10th week of life. This 
period partially overlaps with adolescence [23], leading 
to sexual maturity and early adulthood. Note that, besides 
being prescribed in adults, celecoxib can be also used to 
treat juvenile rheumatoid arthritis in children 2 years and 
older (https://www.accessdata.fda.gov/drugsatfda_docs/la
bel/2011/020998s033,021156s003lbl.pdf).
The mice were exposed whole-body to MCS, 
whereas in humans MCS is inhaled as an undiluted 
complex mixture directly into the respiratory tract and 
therefore its doses are probably even higher than those 
inhaled by mice. The celecoxib dose used (1,600 mg/kg 
diet) was selected based on the results of a preliminary 
subchronic toxicity study in which administration of the 
drug to smoke-free, post-weanling mice for 6 weeks did 
not cause any body weight or behavioral alterations [18]. 
Although this dose is rather high, it is similar or even 
lower than those used in most animal studies available 
in the literature. Furthermore, it is of the same order of 
magnitude as the pharmacological doses used in humans. 
In fact, it has been reported that 1,000 mg/kg diet of 
celecoxib results in a plasma concentration of 1.6 μg/
ml in mice, which approximates the reported therapeutic 
plasma concentration of celecoxib in humans [6]. In 
this comparison, it should be taken in mind that, while 
celecoxib in humans is administered once or twice per 
day, mice eat continuously depending on their metabolic 
needs, which results in a highly fractionated drug intake 
with the diet.
Exposure of both Swiss H mice and ICR (CD-1) 
mice to MCS during the first 10 weeks of life resulted 
in the massive formation of bulky DNA adducts to lung 
DNA, which was documented by autoradiographic 
DRZs. These patterns are typical of exposures to complex 
mixtures such as CS [24]. Later on, exposure of H 
mice to MCS during the first 4 months of life caused a 
systemic genomic damage, which was demonstrated by a 
significant increase of micronuclei in the erythrocytes. The 
contribution of oxidative mechanisms to the formation of 
MCS-related nucleotide alterations was supported by the 
parallel sharp increase of 8-oxo-dGuo in mouse lung in 
Swiss H mice. Likewise, high levels of DNA adducts were 
detected in the heart of MCS-exposed ICR (CD-1) mice, 
whereas just a marginal increase was appreciable in their 
liver. These findings are in agreement with the results of 
previous studies in adult rats exposed to ECS. The main 
difference between lung and heart is that DNA adduct 
levels rapidly decline in the lung upon discontinuation of 
exposure to CS, whereas they are more persistent in the 
heart, presumably due to a lower efficiency of DNA repair 
mechanisms [25]. Cell proliferation is another distinctive 
mechanism between lung and heart. In fact, the cells of 
the bronchoalveolar tract are characterized by a high 
proliferation rate, while cardiomyocytes are perennial cells 
after birth. Accordingly, while the presence of nucleotide 
alterations in the lung are predictive of a possible evolution 
towards cancer, no such evolution can be envisaged in the 
heart, because cell proliferation is a condicio sine qua non 
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for the formation of neoplastic diseases. Rather, nucleotide 
alterations in cardiomyocytes are possibly related to an 
evolution towards genuinely degenerative heart diseases 
[26, 27].
A rather unexpected finding was that treatment with 
celecoxib caused the evident formation of DNA adducts in 
both mouse lungs and heart. In fact, the oral administration 
of this NSAID after weanling, from the 5th to the 10th 
week of life, resulted in the formation of autoradiographic 
spots, which was not accompanied by any oxidative DNA 
damage. Formation of celecoxib-specific DNA adducts in 
the lung was first demonstrated in the study using Swiss 
H mice (Study 1). In order to validate this finding, we 
carried out a further ad hoc study (Study 2), in which we 
treated mice belonging to another strain [ICR (CD-1)] 
according to the same protocol. The results confirmed that 
administration of celecoxib to smoke-free mice causes the 
formation of DNA adducts in the lung and, additionally, 
in the heart, whereas this kind of lesion was negligible 
in the liver. These findings are presumably related to the 
distinctive pharmacokinetic and metabolism of this NSAID 
in different organs. It is known that, in various animal 
species, the methyl group of celecoxib is first oxidized 
to a hydroxymethyl metabolite, followed by additional 
oxidation of the hydroxymethyl group to a carboxylic 
acid metabolite [28]. Using human liver microsomes, 
methyl hydroxylation of celecoxib was found to be 
primarily catalyzed by CYP2C9 [29], which is involved 
in the metabolism of endogenous compounds, drugs, and 
procarcinogens, also including CS components [30].
The results of our studies agree with the results of 
another study [31], in which the levels of adducts formed 
by 3H-B(a)P [benzo(a)pyrene] in CS-exposed mice were 
significantly decreased by oral celecoxib in the liver 
but were significantly increased in the lung. These data 
are not coincident with ours, because we evaluated all 
smoke-related DNA adducts and not only those formed 
by BPDE [benzo(a)pyrene diolepoxide]. In addition, as 
we will discuss below, we found that celecoxib decreases 
MCS-related DNA adduct levels. Nevertheless, these 
findings suggest a tissue specificity in the ability of 
celecoxib to form DNA adducts. Koul et al. [31] ascribed 
these differential patterns to the fact that celecoxib 
administration results in a significant decrease of GST 
(glutathione S-transferase) activity in the lung but not in 
the liver, which may justify an impaired detoxification of 
the celecoxib reactive metabolite(s) in the lung.
On the other hand, celecoxib inhibited the formation 
of MCS-related DNA adducts in the heart and, even more 
efficiently, in the lung. This demonstrates that celecoxib 
exerts protective effects towards induction of nucleotide 
alterations in MCS-exposed mice and that the overall 
protective effects resulting from co-treatment of mice 
with MCS and celecoxib are prevalent as compared with 
the DNA damage produced by this COX-2 inhibitor when 
given to MCS-free mice. These results are consistent with 
the finding that celecoxib is able to exert protective effects 
in Swiss H mice exposed to MCS. In particular, besides 
attenuating preneoplastic alterations in the urinary tract, 
celecoxib decreased the multiplicity of MCS-induced lung 
adenomas. Moreover, the yield of lung malignant tumors 
was lower in MCS-exposed mice treated with celecoxib 
compared to those MCS-exposed mice that did not receive 
the chemopreventive regimen. However, at the same 
dose used in the present study, celecoxib became toxic to 
MCS-exposed mice and some signs of hepatotoxicity were 
detected in MCS-exposed mice treated with celecoxib 
[18]. In humans, a case-control study showed that use 
of selective COX-2 inhibitors, among which celecoxib, 
reduced the lung cancer risk [12], and a trial of celecoxib 
in former smokers decreased the bronchial Ki-67 labeling 
index and reduced lung nodules on computed tomography 
[13]. In human lung carcinoma H1299 cells, celecoxib 
suppressed several molecular alterations induced by a CS 
condensate [32].
In addition to genomic damage, exposure of mice to 
MCS resulted in multiorgan epigenetic alterations, in the 
form of dysregulation of miRNA profiles. MCS induced 
a prevalent downregulation of miRNAs in the lung, 
in agreement with previous studies in rats [33, 34] and 
mice [35–43]. The same conclusion was drawn in studies 
evaluating miRNA expression in the bronchial epithelium 
from humans who smoke [44]. The results relative to 
dysregulation of miRNA expression in the lung and blood 
of newborn Swiss H mice (Study 1) and in 10 organs and 
3 body fluids of young Swiss ICR (CD-1) mice (Study 3) 
have been separately reported and commented in previous 
studies in which microarray data had been validated by 
qPCR analyses [22, 42].
Here we will discuss the results relative to 
dysregulation of miRNA expression following 
administration of celecoxib either to smoke-free mice or to 
MCS-exposed mice. In Swiss H mice treated with celecoxib 
after weanling (Study 1), the effects of the drug in the lung 
was mainly in the sense of upregulation. The most intensely 
upregulated miRNAs by celecoxib included miR-106b, 
which is involved in cell adhesion, tumor necrosis factor 
(TNF) activation, and stress response, and miR-582 and 
miR-328, both of which are involved in cell proliferation 
and apoptosis. Two of the miRNAs upregulated by 
celecoxib in mouse lung (miR-181, miR-208a) were also 
upregulated in the blood serum, but most miRNAs whose 
concentrations were increased in the blood were unaffected 
in the lung. It is conceivable that celecoxib-related miRNAs 
in blood serum reflect molecular changes induced by this 
drug not only in lung but also in other organs bearing 
relevance for the pharmacodynamic activity of this drug, 
such as liver and heart. In fact, besides miR-208a, which 
has been related to the occurrence of heart damage (see 
below), 7 of the 18 blood miRNAs altered by celecoxib 
are liver specific. Similar conclusions were drawn by 
evaluating miRNA dysregulation by celecoxib in 10 organs 
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and 3 body fluids of Swiss ICR (CD-1) mice (Study 3). 
In fact, the drug induced the release of miRNAs into the 
blood mainly from kidney, stomach, and liver. These organs 
are established targets of this COX-2 inhibitor for both 
protective and adverse effects (gastritis and nephrotoxicity). 
A similar situation occurred in the BALF, although the 
number of miRNAs altered by celecoxib was by far lower 
than in blood. These finding indicate that celecoxib, 
administered with the diet, does not preferentially target the 
lung, this organ being only a secondary target as compared 
to kidney, stomach, liver, and spleen. In contrast, it is 
likely that the miRNAs released into BALF reflect plasma 
ultrafiltration processes contributing to the production of 
bronchial mucus. Kidney, stomach and bladder were the 
main contributors of miRNAs modulated by celecoxib 
treatment in urine.
The comparison of miRNA profiles in mice treated 
with celecoxib, either exposed or unexposed to MCS, 
was investigated in order to assess which biological fluid 
better predicts the preventive effects of this drug against 
miRNA alterations induced by MCS. In the blood, the 
great contribution of kidney and bladder is consistent with 
the fact that these organs are targets for both celecoxib and 
MCS. The spleen contribution, being this organ widely 
populated by immune-competent cells, reflects the specific 
anti-inflammatory activity of celecoxib against MCS-
induced inflammation. The analysis of BALF further 
supported the fact that lung is just a secondary target 
for celecoxib as compared to other organs. In urines, the 
number of modulated miRNAs was low.
Among other miRNAs modulated by celecoxib, 
it is of interest that miR-21 was downregulated both in 
the stomach and in the blood of ICR (CD-1) mice treated 
with this NSAID. This miRNA had been found to be 
upregulated in cultured human gastric adenocarcinoma 
cells treated with nicotine, which also stimulated COX-2/
prostaglandin E (PGE) signaling via modulation of NF-κB 
activity [45]. In the present study, the transcription factor 
NF-κB was targeted by a number of miRNAs in organs and 
body fluids of celecoxib-treated mice, either smoke-free 
and/or MCS-exposed. In particular, celecoxib-modulated 
miRNAs that target NF-κB included members of the miR-
30 family, such as miR-30a (lung), miR-30b (liver, heart, 
kidney, colon, heart, spleen, urinary bladder), miR-30c-
1-3p (stomach, urinary bladder), miR-30c-2-3p (lung, 
kidney, spleen, urinary bladder), miR-30c-5p (liver, heart, 
kidney, spleen, stomach, skeletal muscle, blood, BALF), 
miR-30d (lung, skeletal muscle), and miR-30e (lung, liver, 
kidney, urinary bladder, skeletal muscle, blood); members 
of the miR-181 family, including miR-181b (lung, urinary 
bladder, stomach, BALF), miR-181c-3p (lung, stomach), 
miR-181c-5p (urinary bladder, skeletal muscle), and miR-
181d (lung, stomach, urinary bladder); and miR-185-3p 
(kidney, stomach, spleen, skeletal muscle).
By comparing the data obtained in celecoxib-
treated mice, either unexposed or exposed to MCS, it is 
noteworthy that 10 miRNAs (miR-106a, miR-290, miR-
381, miR-471, miR-615, miR-758, miR-1247, miR-3070, 
miR-3085, and miR-3109) were upregulated by celecoxib 
in the lung of both sham-exposed and MCS-exposed 
newborn Swiss H mice, while no miRNA was modulated 
by celecoxib in the lung of both sham-exposed and MCS-
exposed adult ICR (CD-1) mice. Although we cannot rule 
out possible interstrain differences, these results show a 
sharp difference in the epigenetic response to this NSAID 
when administered for 6 weeks either to post-weanling 
mice exposed to MCS since birth or to adult mice in 
which treatment with celecoxib started shortly before the 
first exposure to MCS. Such an age-related difference was 
also confirmed by the finding that 6 miRNAs (miR21/21a, 
miR-185, miR-335, miR-361, miR-695, and miR-1964) 
were upregulated by celecoxib in the blood serum of MCS-
free Swiss H mice, while all of them were downregulated 
in the blood serum of young adult ICR (CD-1) mice. Four 
miRNAs (miR-181-b/c, miR-471, miR-511/511b, and 
miR-1247) were upregulated by celecoxib in the lung of 
both MCS-free newborn Swiss H mice and young adult 
ICR (CD-1) mice. Two miRNAs (miR-185, and miR-335) 
were downregulated by celecoxib in the blood serum of 
both sham-exposed and MCS-exposed ICR (CD-1) mice. 
The same two miRNAs were downregulated by celecoxib 
in both lung and blood serum of MCS-exposed ICR (CD-
1) mice. It is noteworthy that, in MCS-exposed mice, 
miR-185 was modulated both in lung and blood serum at 
both low and high celecoxib doses. Therefore, this miRNA 
represents a blood biomarker that reflects the protective 
effect exerted by this COX-2 inhibitor in the lung.
There are concerns regarding the cardiotoxicity of 
several agents used both in cancer treatment and in cancer 
prevention [46], among which the case of celecoxib 
is paradigmatic [9, 10]. In addition to the previously 
discussed formation of bulky DNA adducts in the heart of 
mice treated with celecoxib, it was of interest to evaluate 
modulation by this drug of those miRNAs that are known 
to target the heart. Of the miRNAs analyzed in the present 
study, miR-308 was upregulated by celecoxib in the blood 
serum of MCS-free neonatal Swiss H mice, and miR-
208 was upregulated in both lung and blood serum of the 
same mice. In adult ICR (CD-1) mice, miR-30c-5p was 
downregulated in several organs, among which heart, and 
in the blood serum of MCS-free mice. Within the same 
miRNA family, miR-30b was downregulated in the heart 
of both MCS-free and MCS-exposed mice.
Of the above mentioned miRNAs, miR-30 plays a 
role in myocardial matrix remodeling [47] and contributes 
to endoplasmic reticulum stress in cardiac muscle and 
vascular smooth muscle cells [48]. miR-208 has been 
included in the list of muscle-specific miRNAs, called 
myomiRs, and has extensively been investigated both 
in cardiomyocyte development [49] and heart injury 
[50]. As inferred from studies in rats, this miRNA has 
been proposed as a plasmatic biomarker of myocardial 
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injury [51] and other cardiovascular diseases [52]. In 
addition, miR-208 has been suggested to be a potent 
therapeutic target for the modulation of cardiac function 
and remodeling during heart disease progression 
[53]. From a mechanistic point of view, it has been 
proposed that downregulation of miR-208 contributes 
to reactive oxygen species (ROS) production in mouse 
cardiomyocytes and enhances apoptosis of these cells 
mainly by targeting p21 [54]. The same considerations 
may hold true for miR-328, the other miRNA that we 
found to be increased in the blood serum of celecoxib-
treated Swiss H mice. In fact, studies in humans showed 
that circulating miR-328 could be a potential indicator for 
heart injury, and the levels of this miRNA are associated 
with increased risk of mortality or development of acute 
myocardial infarction [55], cardiac hypertrophy [56], and 
atrial fibrillation [57].
Our finding that both miR-208 and miR-328 are 
upregulated in mice treated with celecoxib early in life is 
new and may contribute to understand the cardiovascular 
effects produced by this selective COX-2 inhibitor. 
Accordingly, it may be assumed that maintenance of these 
miRNAs at an appropriate level in the blood of celecoxib-
treated individuals may be taken as a safety indicator in 
order to avoid possible adverse effects of this drug on the 
cardiovascular system.
In conclusion, the results of the three studies 
reported in the present article show that celecoxib is able 
to attenuate the DNA alterations produced by MCS in 
mouse lung in terms of bulky DNA adducts and oxidative 
DNA damage. Moreover, celecoxib counteracted the 
MCS-related dysregulation of several miRNAs in a variety 
of organs and body fluids thereby suggesting that this 
NSAID has pleiomorphic properties. Such a conclusion is 
in agreement with the hypothesis that NSAIDs may reduce 
the “inflammogenesis of cancer” not only by interfering 
with the arachidonic acid cascade but also through 
multiple mechanisms [2, 58, 59]. CS induces inflammation 
also by blocking miRNA maturation at the DICER level, 
thus causing accumulation of miRNA precursors in 
cytoplasm that trigger TLR (toll-like receptor) activation 
[60, 61]. The findings of the present studies evaluating 
genomic and epigenetic biomarkers are consistent with 
the results of a parallel medium-term bioassay in Swiss 
H mice in which celecoxib attenuated the MCS-induced 
alterations of inflammatory nature, the yield of lung 
adenomas, and progression to cancer in the lung [18].
On the other hand, administration of celecoxib 
to non-smoking mice resulted in evident molecular 
alterations. These included the selective formation 
of bulky DNA adducts in both lung and heart and the 
dysregulation of a number of miRNAs in various organs, 
also including those miRNAs that are heart-specific and 
have been involved in cardiovascular diseases, which may 
bear relevance in the pathogenesis of the cardiovascular 
adverse effects of this drug.
MATERIALS AND METHODS
General design of the studies
In all 3 studies the mice were divided into the 
following 4 groups: (a) mice kept in filtered air (sham); 
(b) mice treated with celecoxib; (c) mice exposed to MCS; 
and (d) mice exposed to MCS and treated with celecoxib. 
Study 1 evaluated the levels of bulky DNA adducts and the 
intensity of oxidative DNA damage in lung, the frequency 
of micronucleated normochromatic erythrocytes (MN 
NCE) in the blood, and the expression of miRNAs in both 
lung and blood of Swiss H mice as related to exposure to 
MCS for 10 weeks, starting at birth, and administration of 
celecoxib after weanling (about 4 weeks) until the 10th 
week of life. Ten mice per group (5 males and 5 females) 
were used. Study 2 evaluated the levels of bulky DNA 
adducts in the lung, liver, and heart of Swiss ICR (CD-
1) mice as related to exposure to MCS for 10 weeks, 
starting at birth, and administration of celecoxib after 
weanling (about 4 weeks) until the 10th week of life. 
Twenty mice per group (10 males and 10 females) were 
used. Study 3 evaluated the expression of miRNAs in 10 
organs, including lung, liver, heart, kidney, spleen, urinary 
bladder, skeletal muscle (left gastrocnemius), colon, 
stomach, and brain, and 3 body fluids, including blood 
serum, bronchoalveolar lavage fluid (BALF), and urines, 
of two-month old Swiss ICR (CD-1) mice, as related 
to exposure to MCS for 8 weeks and administration of 
celecoxib for the same period, starting 3 days before 
exposure to MCS. Each group was composed of 10 female 
mice.
Mice
Strain H neonatal mice, used in Study 1, were 
born at the Animal Laboratory of the National Center of 
Oncology (Sofia, Bulgaria). The mice were housed in 
Makrolon™ cages on sawdust bedding and maintained 
on standard rodent chow (Kostinbrod, Bulgaria) and 
allowed drinking water ad libitum. Swiss ICR (CD-1) 
mice, either neonatal (Study 2) or two- month old (Study 
3), were purchased from Harlan Laboratories (San Pietro 
al Natisone, Udine, Italy). The mice were housed in 
Makrolon™ cages on sawdust bedding and maintained on 
standard rodent chow (Teklad 9607, Harlan Laboratories) 
and tap water ad libitum. The animal room temperature 
was 23 ± 2°C, with a relative humidity of 55% and a 12 h 
day-night cycle. Housing and treatments of mice were in 
accordance with NIH, European (2010/63 UE Directive), 
and institutional guidelines. The issuance of the NIH 
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Office of Laboratory Animal Welfare (OLAW) with the 
University of Genoa bears the identification number 
A5899-01 and is effective until February 28, 2021. The 
Institutional Animal Care and Use Committee (IACUC) 
protocol was approved by the Fox Chase Cancer Center 
Committee on April 13, 2015.
Exposure to MCS
A whole-body exposure of the mice to MCS was 
achieved as previously described [20, 22], by using 3R4F 
Kentucky reference cigarettes (College of Agriculture, 
The Reference Cigarette Program, University of 
Kentucky, Lexington, KY), having a declared content of 
9.4 mg tar, 0.73 mg nicotine, and delivering 12 mg of CO 
each when burned. MCS was delivered to the exposure 
chambers by drawing 15 consecutive puffs, each of 60 ml 
and lasting 6 s. Each daily session involved 6 consecutive 
exposures, lasting 10 min each, with 1 min intervals 
during which a total air change was made. Exposure 
started either within 12 h after birth (Study 1 and Study 2) 
or at the age of 2 months (Study 3) and continued daily for 
8-10 weeks. The average total particulate matter (TPM) 
concentrations in the exposure chambers were 689 mg/
m3 in Study 1, 737 mg/m3 in Study 2, and 784 mg/m3 in 
Study 3.
Administration of celecoxib
Celecoxib was supplied by the US National Cancer 
Institute (NCI) via MRIGlobal (Kansas City, MO). Based 
on a preliminary subchronic toxicity study in Swiss H mice 
[18], it was decided to incorporate celecoxib in the mouse 
diet at the dose of 1,600 g/Kg diet, which corresponded to 
the 80% of the maximum dose that did not produce any 
bodyloss or sufferance or alterations in the behavior of 
smoke-free mice after 6 weeks of treatment. Moreover, 
in Study 3 two additional groups of female mice, either 
smoke-free or MCS-exposed, received low dose celecoxib 
(20 mg/kg diet).
In Study 1 and Study 2, feeding of the drug-
containing diet started after weanling (about 4 weeks) 
and continued until the 10th week of life. In Study 3, 
administration of celecoxib with the diet started 3 days 
before the first exposure to MCS and continued until the 
end of the experiment (8 weeks).
Euthanasia of mice and collection of organs and 
body fluids
At the end of each experiment, the mice were 
euthanized. Each mouse was transferred into a separate 
chamber and isolated from the other mice. The 2013 
American Veterinary Medical Association (AVMA) 
guidelines on euthanasia were followed using slow 
introduction of CO2 asphyxiation, and death was 
confirmed by absence of respiration and/or heartbeat.
The urine was collected for 8 h and pooled from the 
mice belonging to each experimental group in Study 3 by 
using metabolic cages during the day preceding euthanasia 
of mice. Immediately after sacrifice, a bronchoalveolar 
lavage (BAL) was performed and used for preparing 
BALF, and the blood was collected and used for preparing 
serum. BALF and blood serum were pooled within each 
experimental group. The organs reported in the general 
design of the studies were collected, as previously 
described [22]. Immediately after collection, each organ 
or fluid was immersed in RNAlater and kept at -80°C for 
miRNA analysis. Portions of the organs used in Study 
1 and Study 2 were stored at -80°C for evaluating DNA 
damage. Moreover, in order to evaluate the frequency 
of MN NCE, the blood was collected from the lateral 
tail vein of 40 neonatal Swiss H mice (20 males and 20 
females), used in parallel experiments [18], which were 
exposed to MCS and/or treated with celecoxib until the 
4th month of life.
Extraction and 32P postlabeling analysis of lung 
DNA
DNA was extracted from tissue specimens (50 
mg) collected individually from the lungs of 40 Swiss 
H mice used in Study 1 and from lungs, heart and liver 
of 80 ICR (CD-1) mice used in Study 2, as previously 
described [23]. Bulky DNA adducts, after butanol 
enrichment, and 8-hydroxy-2’-deoxyguanosine (8-oxo-
dGuo) were measured by 32P postlabeling as previously 
described [62].
Modulation of the systemic MCS genotoxicity
At 4 months of age, immediately after discontinuing 
exposure to MCS, peripheral blood was collected from the 
tail lateral vein and smeared onto slides (2 slides/mouse) 
from 20 mice (10 males and 10 females) per each one 
of the 4 experimental groups. After staining with May-
Grünwald-Giemsa, the frequency of MN NCE was scored 
by analyzing microscopically 50,000 NCE/mouse.
Extraction of RNA and analysis of miRNA 
expression in mouse organs and body fluids
RNA was extracted from mouse organs (miRNeasy, 
Qiagen, Hilden, Germany) and body fluids (Exiqon’s 
miRCURY™ RNA Isolation Kit – Biofluids (Exiqon, 
Vedbaek, Denmark) according to the manufacturers’ 
instructions. The quality of the RNA extracted was 
evaluated by spectrophotometric analyses using a fiber 
optic spectrophotometer (Nanodrop ND-1000).
For evaluating the expression of pulmonary 
miRNAs we used the 7th generation miRCURY LNA™ 
microRNA Array (Exiqon), which contains 3,100 capture 
probes covering human, mouse and rat miRNAs. In 
particular, this array covers 1,135 mouse miRNAs, i.e. 
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the 88.6% of the 1,281 mouse miRNAs listed in miRBase 
19. Microarray analyses were carried out as previously 
described [22].
Microarray data have been recorded in the GEO 
database (GEO accession No. requested).
Statistical analysis
Treatment-related differences in body weights, in 
the frequency of MN NCE, and in the levels of pulmonary 
DNA adducts and 8-oxo-dGuo, all of them expressed as 
means ± SE within each group of mice, were evaluated for 
statistical significance by ANOVA followed by Student’s 
t test for unpaired data. miRNA microarray data, after 
local background subtraction, log transformation, and 
normalization were analyzed by GeneSpring software 
(Agilent, Santa Clara, CA), and expression data were 
median centered by using the GeneSpring normalization 
option. The statistical significance of the differences 
between experimental groups was evaluated by means 
of the GeneSpring ANOVA applied by using Bonferroni 
multiple testing correction. As inferred from volcano-plot 
analysis, differences between sets of data were taken as 
significant when they were both statistically significant 
(P < 0.05) and showed at least a two-fold variation. 
The overall variability of microarray data, as related 
to treatments, was evaluated by scatter-plot analysis 
(SPA), hierarchical cluster analysis (HCA), and principal 
component analysis (PCA).
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